...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatric blood & cancer >Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study
【24h】

Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study

机译：伊立替康和卡铂同时放射治疗中，高危横纹肌肉瘤：一项前瞻性II期试验研究的毒性和疗效报告

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Irinotecan is highly active against rhabdomyosarcoma (RMS), yet its tolerability and efficacy in combination with radiation is unknown. We examined local control and toxicities in RMS patients treated with radiotherapy (RT) in combination with radiosensitizing agents irinotecan+carboplatin (I+C). Procedure: From 11/2003 to 1/2011, 60 patients were enrolled on a pilot phase II protocol with newly diagnosed intermediate- or high-risk RMS at Memorial Sloan-Kettering Cancer Center. Induction therapy consisted of two cycles of I+C followed by three cycles of vincristine, doxorubicin, and cyclophosphamide. At week 13, 47 patients received definitive primary-site RT or post-operative RT with two concurrent cycles of I+C. Median RT dose was 50.4Gy (range 30.6-50.4Gy). Radiation-related toxicities were evaluated according to the Common Terminology Criteria for Adverse Events, version 3.0. Results: Median age of the cohort was 9 years. With median follow-up of 32 months, 2.5 year actuarial local control was 89%. Among all patients, grades 3 and 4 dermatitis were observed in 11% and 4%, respectively. Among parameningeal, orbit, and other headeck sites, rates of grades 3 and 4 mucositis were 20% and 10%, respectively. Among abdomen/pelvis sites, 12% developed grade 3 diarrhea and 6% developed grade 3 cystitis. No treatment breaks were necessary. Conclusions: Preliminary results of irinotecan and carboplatin administered with concurrent RT in intermediate- and high-risk RMS demonstrated favorable tolerability, efficacy, and local control. Reduced rates of acute grades 3-4 mucositis were observed when compared with historical results.
机译：背景：伊立替康对横纹肌肉瘤（RMS）具有很高的活性，但其耐受性和与放射线结合使用的功效尚不清楚。我们检查了放疗（RT）与放射增敏剂伊立替康+卡铂（I + C）结合治疗的RMS患者的局部控制和毒性。程序：从11/2003到1/2011，在纪念斯隆-凯特琳癌症中心接受60例初诊II期试验的新诊断为中危或高危RMS的患者。诱导治疗包括两个周期的I + C，然后是三个周期的长春新碱，阿霉素和环磷酰胺。在第13周，有47位患者接受了明确的原位RT或术后RT，同时进行了两个I + C周期。 RT剂量中位数为50.4Gy（范围30.6-50.4Gy）。根据《不良事件通用术语标准》（3.0版）评估了与辐射有关的毒性。结果：该队列的中位年龄为9岁。中位随访32个月，2.5年精算局部控制率为89％。在所有患者中，分别观察到11％和4％的3级和4级皮炎。在脑膜旁，眼眶和其他头/颈部位，3级和4级粘膜炎的发生率分别为20％和10％。在腹部/骨盆部位，有12％发生3级腹泻，而6％发生3级膀胱炎。无需中断治疗。结论：伊立替康和卡铂同时进行RT的中，高风险RMS的初步结果显示良好的耐受性，疗效和局部控制。与历史结果相比，观察到急性3-4级粘膜炎的发生率降低。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号